Millennium Management LLC Has $4.73 Million Position in Flexion Therapeutics, Inc. (NASDAQ:FLXN)

Millennium Management LLC boosted its stake in shares of Flexion Therapeutics, Inc. (NASDAQ:FLXN) by 39.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 575,046 shares of the specialty pharmaceutical company’s stock after acquiring an additional 161,982 shares during the quarter. Millennium Management LLC owned 1.14% of Flexion Therapeutics worth $4,733,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Citigroup Inc. increased its stake in shares of Flexion Therapeutics by 60.2% in the second quarter. Citigroup Inc. now owns 288,428 shares of the specialty pharmaceutical company’s stock valued at $2,374,000 after buying an additional 108,353 shares in the last quarter. Susquehanna Fundamental Investments LLC increased its stake in shares of Flexion Therapeutics by 644.6% in the second quarter. Susquehanna Fundamental Investments LLC now owns 82,080 shares of the specialty pharmaceutical company’s stock valued at $676,000 after buying an additional 71,056 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of Flexion Therapeutics by 1.1% in the second quarter. JPMorgan Chase & Co. now owns 734,166 shares of the specialty pharmaceutical company’s stock valued at $6,041,000 after buying an additional 8,012 shares in the last quarter. Alliancebernstein L.P. increased its stake in shares of Flexion Therapeutics by 22.6% in the second quarter. Alliancebernstein L.P. now owns 58,600 shares of the specialty pharmaceutical company’s stock valued at $482,000 after buying an additional 10,800 shares in the last quarter. Finally, Commonwealth Equity Services LLC increased its stake in shares of Flexion Therapeutics by 7.7% in the second quarter. Commonwealth Equity Services LLC now owns 73,185 shares of the specialty pharmaceutical company’s stock valued at $602,000 after buying an additional 5,229 shares in the last quarter. Institutional investors own 90.01% of the company’s stock.

A number of analysts have recently weighed in on the company. Needham & Company LLC lowered Flexion Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 12th. The Goldman Sachs Group decreased their price target on Flexion Therapeutics from $8.00 to $6.00 and set a “neutral” rating on the stock in a report on Friday, August 6th. Credit Suisse Group cut Flexion Therapeutics from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $14.00 to $10.00 in a report on Monday, October 11th. Raymond James cut Flexion Therapeutics from a “strong-buy” rating to a “market perform” rating in a report on Tuesday, October 12th. Finally, HC Wainwright cut Flexion Therapeutics from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $25.00 to $10.00 in a report on Tuesday, October 19th. Eight investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $11.72.

NASDAQ FLXN opened at $9.12 on Thursday. The firm has a market cap of $458.93 million, a P/E ratio of -4.54 and a beta of 1.53. The stock’s 50-day moving average is $8.21 and its 200-day moving average is $7.55. Flexion Therapeutics, Inc. has a one year low of $4.30 and a one year high of $13.66.

Flexion Therapeutics Profile

Flexion Therapeutics, Inc operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain.

Featured Article: Google Finance Portfolio Tips and Tricks

Want to see what other hedge funds are holding FLXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Flexion Therapeutics, Inc. (NASDAQ:FLXN).

Institutional Ownership by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.